Big Pharma has largely exited the antibiotics arena in the past several years, contributing to the dearth of products in the global pipeline as rising antimicrobial resistance becomes a very real public health threat.
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
In 2008, the U.S. National Institutes of Health began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing.
New technology like organs-on-chips and bioprinted tissues have the potential to test the safety of drugs more accurately and cost-efficiently for a myriad of diseases. FierceBiotech Research highlights some organizations that are working on alternative drug testing technology.
Some say the recent allegations about a potential stem cell breakthrough unveiled in January by a major Japanese research institution represent a larger problem of irreproducibility in early science research. But others, like Edward Ahn, managing director and chief science officer of Cambridge, MA-based MedCap Advisors, think we shouldn't jump to conclusions quite yet.
These alliances benefit not only pharma companies, which gain access to world-class scientists and robust drug discovery programs, but also academic institutions, which increasingly are realizing that relationships with Big Pharma are more and more vital.
At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery. Read more >>
Embryonic stem cell research has yet to live up to all the hype. So far, human embryonic stem cells, or hESCs, haven't yielded any cures or therapies to treat diseases. Read more >>
Inking big deals with pharma giants Bristol-Myers Squibb and AstraZeneca, Vanderbilt has emerged as a leading institution for central nervous system drug research and discovery by bringing a business-like approach to the lab.
Stem cell-based therapeutics are a fast-growing area of early-stage biotech research, but they need better production methods to enable large-scale R&D.